Veristat appoints James Roach, M.D. as chief medical officer

Monday, November 7, 2016

Veristat has appointed James (Jim) Roach, M.D., FACP, FCCP as its new chief medical officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings. Dr. Roach will assume his position of chief medical officer on December 2, 2016. In this role, he will lead and grow the clinical operations, medical writing, medical monitoring, safety/pharmacovigilance and regulatory affairs teams at Veristat.

[Read More]

Ambrx appoints Macartney as CEO

Tuesday, January 8, 2013

Ambrx, a clinical-stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, has appointed Lawson Macartney, Ph.D., DVM, as president and CEO of the company and a member of the board of directors.

[Read More]